If you’re a health and life sciences enterprise looking to make a positive impact on the health of your business, your people and the world, Toronto is a thriving metropolis that invests over 1 billion dollars in clinical research every year!
Toronto has asserted itself as a leading location for some of the worlds most prolific healthcare corporations who’ve established innovation centres and incubators in the Toronto Region.
More than 11,000 researchers & technicians operate out of the Toronto Region’s 37 research institutes, 9 teaching hospitals, and the University of Toronto’s Faculty of Medicine, with over $1B in research funding.
53 of the world’s top 100 life science multinationals and 16 of the top 25 global medical device companies operate in the Toronto Region. More than half of Canada’s pharmaceutical companies are based here.
In 2017 alone there were over 140 venture capital and private equity deals in life sciences here in Canada – totalling over 1B in funding collectively.
In September 2015, the Structural Genomics Consortium (SGC) and the Ontario Institute for Cancer Research (OICR), made a major announcement. Together, they’ve developed a new, highly-specific pre-drug molecule called OICR-9429, (referred to as a chemical probe) that could be used as a tool for drug discovery to research some of the world’s most perplexing diseases.
Mark Elias, a Canadian Engineer, took a different approach to treating those affected by Parkinsons tremmors. He developed a wearable glove and other garments that combine innovative technology and comfort. “It uses a smart fluid designed to provide instant and equal resistance to hand tremors”. The product provides several consumer-friendly features such as being washable, requiring no batteries, being adjustable to different tremor levels as well as its lightweight design.
Since 2011, the young company has been looking to provide an economical solution to the climbing expenses involved in the excessive amount of forms mandated by regulating bodies. AcuteNet is able to make this process less painful for the industry through the digitization and workflow automation of medical forms, cloud computing available from any device anytime anywhere, versatile integration capabilities that work with any existing network infrastructure and multi-layer encryption enabling trusted security and online and offline accessibility.
Bayer AG and Versant Ventures have dedicated $295 million ($225 million USD) to launching BlueRock Therapeutics, a stem cell company that will work in collaboration with institutions from Canada, the US, and Japan. BlueRock will have research and development operations in Toronto, New York, and Boston.
We’ve curated a calendar of health science events in the Toronto Region to make it easier for for you to discover local stakeholders and meet your next opportunity.